[Antithrombotic treatment protocols in interventional cardiology]

Area of Science:

• Interventional Cardiology
• Pharmacology
• Biomarkers

Background:

• Coronary stenting is standard practice, necessitating daily anti-platelet therapy.
• Current anti-platelet regimens include aspirin with ticlopidine or clopidogrel.
• Anti-GP IIb/IIIa agents and enoxaparin are crucial in acute coronary syndromes.

Purpose of the Study:

• To highlight the need for a rapid biological test to assess thienopyridine efficacy.
• To identify patients with potential drug resistance to anti-platelet therapies.
• To emphasize optimal antithrombotic strategies in acute coronary syndromes.

Main Methods:

• Review of current anti-platelet and antithrombotic drug use in interventional cardiology.
• Discussion of diagnostic needs for drug resistance.
• Evaluation of treatment options for acute coronary syndromes.

Main Results:

• The combination of clopidogrel and aspirin may replace ticlopidine and aspirin.
• A rapid test for thienopyridine efficacy is needed to detect drug resistance.
• Troponin levels can guide the selection of high-risk patients for aggressive antithrombotic therapy.
• Enoxaparin demonstrates superiority over unfractionated heparin in acute coronary syndromes.

Conclusions:

• Developing a rapid biological test for thienopyridine efficacy is essential.
• Personalized antithrombotic strategies improve outcomes in interventional cardiology.
• Enoxaparin is a preferred anticoagulant for specific acute coronary syndromes.